First human test: does a damaged liver change how a new drug works?
NCT ID NCT07394309
Summary
This is an early safety study to understand how a new drug for liver fibrosis, called hydronidone, is processed by the body in people with different levels of liver damage. It will enroll 30 people, including those with mild to moderate liver impairment and others with healthy livers. Each participant will take a single dose, and researchers will closely measure how the drug moves through their bodies to see if liver problems change its effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.